804 related articles for article (PubMed ID: 34183681)
41. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
[TBL] [Abstract][Full Text] [Related]
42. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model.
Halfmann PJ; Kuroda M; Armbrust T; Accola M; Valdez R; Kowalski-Dobson T; Rehrauer W; Gordon A; Kawaoka Y
Cell Rep; 2022 Feb; 38(7):110394. PubMed ID: 35139368
[TBL] [Abstract][Full Text] [Related]
43. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection by Type and Frequency of Vaccine: A Community-Based Case-Control Study.
Gim H; Seo H; Chun BC
J Korean Med Sci; 2024 Jun; 39(21):e174. PubMed ID: 38832478
[TBL] [Abstract][Full Text] [Related]
44. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
Front Immunol; 2022; 13():888794. PubMed ID: 35711424
[TBL] [Abstract][Full Text] [Related]
46. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
47. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
48. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
49. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
50. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
Tauzin A; Nayrac M; Benlarbi M; Gong SY; Gasser R; Beaudoin-Bussières G; Brassard N; Laumaea A; Vézina D; Prévost J; Anand SP; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Niessl J; Tastet O; Gokool L; Morrisseau C; Arlotto P; Stamatatos L; McGuire AT; Larochelle C; Uchil P; Lu M; Mothes W; De Serres G; Moreira S; Roger M; Richard J; Martel-Laferrière V; Duerr R; Tremblay C; Kaufmann DE; Finzi A
Cell Host Microbe; 2021 Jul; 29(7):1137-1150.e6. PubMed ID: 34133950
[TBL] [Abstract][Full Text] [Related]
51. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
[TBL] [Abstract][Full Text] [Related]
52. Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.
Debes AK; Xiao S; Colantuoni E; Egbert ER; Caturegli P; Gadala A; Milstone AM
JAMA Intern Med; 2021 Dec; 181(12):1660-1662. PubMed ID: 34398173
[TBL] [Abstract][Full Text] [Related]
53. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
[TBL] [Abstract][Full Text] [Related]
54. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
56. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S
Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893
[TBL] [Abstract][Full Text] [Related]
57. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.
Newman J; Thakur N; Peacock TP; Bialy D; Elrefaey AME; Bogaardt C; Horton DL; Ho S; Kankeyan T; Carr C; Hoschler K; Barclay WS; Amirthalingam G; Brown KE; Charleston B; Bailey D
Nat Microbiol; 2022 Aug; 7(8):1180-1188. PubMed ID: 35836002
[TBL] [Abstract][Full Text] [Related]
58. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
Gilboa M; Mandelboim M; Indenbaum V; Lustig Y; Cohen C; Rahav G; Asraf K; Amit S; Jaber H; Nemet I; Kliker L; Bar-Haim E; Mendelson E; Doolman R; Rubin C; Regev-Yochay G; Kreiss Y
J Infect Dis; 2022 Mar; 225(5):785-792. PubMed ID: 34850049
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
